Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting ...

Ten years after her sexual assault, she discovered that the evidence in her rape kit hadn’t been tested — and neither had ...

San Francisco-based Trace Neuroscience has launched with $101 million in series A funding to develop ALS therapies focused on ...

for the treatment of Amyotrophic Lateral Sclerosis (ALS). The European Commission is scheduled to issue the official decision on the Orphan Designation in December. OMPD will offer Neurizon a range of ...

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...

The FDA initially halted the trials on 16 October after a patient in the Phase II trial (NCT05519839) of the CIC vaccine ...

Scientists are working on a way to restore the production of a protein that is essential for communication in the brain and ...

Amyotrophic lateral sclerosis (ALS) is the most common form of MND and there is currently no cure for the condition which ...

The condition is a rapidly progressive neurodegenerative disorder leading to wasting, paralysis and eventual death from ...